All patients have completed their 15-month visits in the European Phase IIb trial with the diabetes vaccine Diamyd[®]

Diamyd Medical's Phase IIb trial DIAGNODE-2 with the diabetes vaccine Diamyd[®] (GAD65-alum) is expected to present Topline results at the end of September. All patients in the trial where Diamyd[®] is given directly into the lymph node have completed their 15-month visits according to plan.“We have seen a great deal of interest and commitment to the trial from our trial participants, clinics and collaboration partners”, says Johnny Ludvigsson, Professor at Linköping University and Coordinating Investigator for the trial. “There is a great need for new treatments for type 1 diabetes. The